Label Image (Lbl500907693)
Sertraline Hydrochloride Tablet
Product Images NDC 50090-7693
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 50090-7693). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Description (Struct)
Table 3 (Table 3)
This text provides a table displaying common adverse reactions observed in adults with various conditions such as MDD, OCD, PD, PTSD, SAD, and PMDD in placebo-controlled trials. The reactions are compared between patients treated with Sertraline Hydrochloride and Placebo. Adverse reactions include cardiac disorders, eye disorders, gastrointestinal disorders, general disorders, metabolism and nutrition disorders, nervous system disorders, psychiatric disorders, reproductive system and breast disorders, and skin and subcutaneous tissue disorders. Some notable reactions include palpitations, nausea, fatigue, decreased appetite, dizziness, insomnia, agitation, libido decrease, erectile dysfunction, and hyperhidrosis. The table also specifies the percentages of these adverse reactions among patients.*
Table1 (Table1)
This is a table showing the recommended daily dosage of sertraline hydrochloride for patients with Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder (SAD). The starting dose for adults with MDD is 50mg, while the therapeutic range varies for OCD and PD, PTSD, SAD. The recommended dosage for pediatric patients with OCD ranges from 50-200mg depending on their age group.*
Table2 (Table2)
This text provides a comparison of the risk differences in the number of cases of suicidal thoughts or behaviors in placebo-controlled trials of antidepressants for pediatric and adult patients. It shows that in the <18 age group, there were 14 additional patients, in the 18-24 age group, there were 5 additional patients, in the 25-64 age group, there was 1 fewer patient, and in the 65 and older age group, there were 6 fewer patients compared to placebo.*
Image Description (Table4)
This text provides a summary of the most common sexual adverse reactions experienced by men and women in sertraline hydrochloride Pooled Controlled Trials for various conditions like MDD, OCD, PD, PTSD, SAD, and PMDD. The adverse reactions listed include ejaculation failure, libido decrease, erectile dysfunction, ejaculation disorder, and male sexual dysfunction in men. For women, only libido decrease was reported.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
